Other anti-CXCR4-based treatments are on the horizon, including, LY2624587, another anti-CXCR4 monoclonal antibody, which caused dose-dependent apoptosis in vitro and in vivo in human haematologic cancer cells and provided a significant survival benefit in a disseminated lymphoma model [34]. Here, CXCR4 is linked to cancer.